Group III metabotropic glutamate receptors (Group III mGluRs)

Group III metabotropic glutamate receptors (mGluRs) comprise four distinct subtypes—mGluR4, mGluR6, mGluR7, and mGluR8—which are Class C G protein-coupled receptors primarily localized to presynaptic terminals in the central nervous system (Niswender & Conn, 2010). These receptors function as inhibitory autoreceptors and heteroreceptors that regulate the release of glutamate and other neurotransmitters by signaling through Gi/o proteins to inhibit adenylyl cyclase activity (UniProt). In therapeutic contexts, mGluR4 is a highly prioritized target for Parkinson's disease because its activation can modulate the indirect pathway of the basal ganglia to alleviate motor symptoms (Niswender et al., 2016). Meanwhile, mGluR7 and mGluR8 are extensively studied for their roles in modulating anxiety, depression, and epilepsy, whereas mGluR6 is uniquely essential for synaptic transmission in the retina (Cryan et al., 2003; StatPearls). Drug development for this group has shifted toward positive allosteric modulators (PAMs) to achieve better subtype selectivity and avoid the rapid desensitization typically associated with orthosteric agonists (Conn et al., 2009). Overall, Group III mGluRs represent a versatile set of targets for fine-tuning excitatory neurotransmission in various neurological and psychiatric disorders.

Other names

mGluR Group IIIMetabotropic glutamate receptor group IIImGlu4/6/7/8 receptorsGroup 3 metabotropic glutamate receptors

Group III mGluRs (mGluR4, 6, 7, and 8) are primarily coupled to Gi/o proteins, which inhibit the enzyme adenylyl cyclase, leading to a decrease in cyclic AMP (cAMP) levels. They also modulate ion channels, such as inhibiting voltage-gated calcium channels and activating G protein-activated inwardly rectifying potassium (GIRK) channels, which collectively results in the inhibition of neurotransmitter release from presynaptic terminals (Niswender & Conn, 2010; UniProt).